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Abstract / Summary 
The development of gene therapy for clinical use continues to face many hurdles. A major issue 
is the limitation of gene delivery technology. This body of work describes strategies for 
improving the selectivity and efficacy of gene delivery to vascular endothelium, with emphasis 
on delivery to pulmonary vasculature in vivo. Several important principles were established 
which continue to be of relevance to the field. The work progresses from vector development 
through to the use of new vector strategies in the application of novel gene delivery approaches 
in disease models. Work in gene therapy and vector development began in the Division of 
Human Gene Therapy, University of Alabama at Birmingham, under the mentorship of Prof 
David T Curiel and has continued through international collaborations and the establishment of 
my own laboratory in the Hanson Institute with affiliate links to the University of Adelaide. 
The work presented in this thesis consists entirely of published material, either as book chapters 
(three) or peer reviewed journal articles (twelve). The sequence of material progresses from a 
broad introduction to the field on Gene Therapy, more specific chapters dealing with pulmonary 
gene delivery including a detailed methodology chapter. The peer reviewed works contain an 
evolution of work dealing with the development of strategies to target adenoviral gene delivery 
vectors to the pulmonary vascular endothelium. This work encompasses the use of bi-specific 
conjugates, genetic modification of viral capsid (outer coat) proteins and the use of cell-specific 
promoters. The work progresses to a demonstration of the therapeutic gains achieved with the 
use of targeted over non-targeted vectors in animal models and culminates with a highly novel 
application of modulation of the bone morphogenetic protein pathway in pulmonary 
hypertension. A component of the work focuses on enhanced gene delivery to vein grafts ex­
VIVO. 
There are many key original contributions encompassed within the work, including 1) first use of 
conjugate-based retargeting to vascular cells, 2) first demonstration that tropism modification 
could alter in vivo biodistribution of virus, 3) first demonstration of cell-specific retargeting of 
adenoviral vector after systemic vascular injection in vivo (a technique still unsurpassed in the 
field), 4) first demonstration of the in vivo selectivity gains achieved by combined cell-specific 
promoters with viral retargeting, 5) first demonstration of therapeutic gains achieved by targeting 
in a vascular context and 6) first demonstration that modulation of the BMPR2 pathway can have 
a therapeutic impact in pulmonary hypertension. Importantly, the targeting work I have 
developed has been adapted and used by others and laid a foundation for further vector 
improvements. 
